Study Group: Generic Pharmaceuticals Economic Experts (Germany)(?)
Council Members in this Study Group: 35
Request a survey with this Study Group
Leading Experts in this Study Group
![]() |
What is a GLG Leader? |
John Ansell, MBADirector
John Ansell Consultancy
John Ansell, BSc, MA, has been a pharmaceutical industry consultant since 1990, based in Thame, near Oxford, UK. He was employed for 20 years in the industry by Organon, Schering AG, Fisons, Solvay and Glaxo. His experience there and subsequently as a consultant is chiefly in business development, licensing,...
Jan HackerManaging Partner
Oberender & Partner
Jan Hacker is the Managing Partner and Co-founder of Oberender & Partner, a leading Healthcare Consulting Company in Germany. Mr. Hacker has expertise in strategic hospital management and the development of market entry strategies for foreign companies. He is also a member of the board of EconoMedic...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Experts(?)
In 1976, sitting in my office in International Marketing at Fisons, Loughborough, UK, I used to watch the drums of bulk paracetamol arriving at the factory from China - easily recognizable from the Chinese script decorating them. I'm sure the UK wasn't the only country importing raw materials from China...
European approval for Humira in psoriasis is a key step towards leadership over the other monoclonal antibodies already approved - and because this is the most valuable category, leadership also of the total psoriasis market. In April 2007 Abbott submitted this indication for approval to...
Exubera is the first major product to fail primarily due to Pfizer's inability to convince payors of it's value for money There is now significant additional risk in achieving market access after regulatory approval. Pricing and reimbursement decisions will play an increasingly important role in the...
This move conforms with Lundbeck's strategy to concentrate on CNS areas and to bring in other parties to develop non-CNS applications.
Persisting with developing a vaccine for HIV may be no more realistic than attempting to produce one for the common cold. There is a link - both are caused by adenoviruses. If Merck, after 20 years has not succeeded for HIV, shouldn't development resources on vaccines now be channeled to more productive...
Most Common Company Types:
- Consultancy, Healthcare-Focused
- Consultancy, Pharma-Focused
- Pharmacy or Drug Store, Independent/Local
- Academic Institution*
- Pharmaceuticals Manufacturer
- Strategic Management
- Academic Medical Center/Hospital or Clinic
- Drug Distributor, General or Full-Spectrum
- Individual/Small Consultancy
- Law Firm (general practice/large)
- Office Based Private Practice or Clinic
- Professional or Industry Association*
Most Common Job Types:
- Director
- Owner
- Principal
- Consultant
- President
- Project Manager
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms


